Data presented at ACC.26 further demonstrate the benefits of iRhythm’s Zio® ambulatory ECG portfolio across multiple patient populations as company launches new digital education platform

Rhea-AI Summary

iRhythm (NASDAQ: IRTC) reported retrospective ACC.26 analyses showing a high prevalence of clinically actionable arrhythmias across cardiometabolic and kidney-metabolic (CKM) populations and launched iRhythm Academy clinician education. Key findings: 48% arrhythmia prevalence in CKD, 47% with both diabetes+CKD, AF prevalence rose from 4.5% to 6.5% with severe obesity, adjusted AF odds ratio 2.8.

Company highlighted AI scaling in cardiology and announced a Spanish-language update to the MyZio mobile app.

Positive

• High diagnostic yield: 48% arrhythmia prevalence in CKD patients
• Obesity link: AF prevalence rose from 4.5% to 6.5% with severe obesity (adjusted OR 2.8)
• Scale and data: nearly 12 million patient reports and >3 billion curated heartbeat hours
• Education & access: launch of iRhythm Academy and Spanish MyZio app update

Negative

• Retrospective analyses: studies are observational, limiting causal inference and prospective impact estimates

Key Figures

CKD/diabetes cohort size: 657,147 individuals Arrhythmias in CKD: 48% Arrhythmias in diabetes + CKD: 47% +5 more

8 metrics

CKD/diabetes cohort size 657,147 individuals U.S. patients with 14-day continuous ambulatory monitoring

Arrhythmias in CKD 48% Clinically actionable arrhythmias in CKD patients after age adjustment

Arrhythmias in diabetes + CKD 47% Clinically actionable arrhythmias in patients with both diabetes and CKD

Obesity cohort size 162,531 individuals U.S. patients with 14-day long-term continuous monitoring and BMI data

AF prevalence range 4.5% to 6.5% AF detection from normal/underweight to severe obesity groups

AF odds ratio severe obesity 2.8 Adjusted odds ratio vs normal/underweight for AF detection

Arrhythmias preceding diabetes 43% Share of diabetes cases where arrhythmias preceded diagnosis in ADA 2025 data

At-risk U.S. population 27 million people Estimated annual number at risk for undiagnosed arrhythmias in U.S.

Market Reality Check

Price: $118.10 Vol: Volume 460,755 is below t...

normal vol

$118.10 Last Close

Volume Volume 460,755 is below the 20-day average of 651,585, suggesting a relatively subdued reaction pre-ACC.26. normal

Technical Shares at $118.10 are trading below the $160.10 200-day MA and sit 44.29% under the 52-week high of $212.

Peers on Argus

IRTC is down 3.83%, while several medical device peers (GKOS, BIO, BRKR, GMED) s...

IRTC is down 3.83%, while several medical device peers (GKOS, BIO, BRKR, GMED) show declines between -2.26% and -3.88%, indicating broader sector weakness with MASI roughly flat.

Historical Context

5 past events · Latest: Mar 12 (Positive)

Pattern 5 events

Date	Event	Sentiment	Move	Catalyst
Mar 12	Board appointment	Positive	-1.5%	New independent director added to support scaling and strategic growth.
Feb 19	Earnings release	Positive	-5.0%	Strong Q4 and FY25 revenue growth, margin expansion, and guidance.
Feb 05	Earnings date set	Neutral	-0.2%	Announcement of timing and webcast details for Q4/FY results.
Jan 12	Conference update	Positive	-5.8%	Preliminary 2025 revenue above guidance and 2026 growth outlook shared.
Dec 29	Conference notice	Neutral	-0.0%	Notice of upcoming presentation at J.P. Morgan Healthcare Conference.

Pattern Detected

Recent positive corporate and financial updates have often coincided with modest to notable share price declines within 24 hours.

Recent Company History

Over the past several months, iRhythm has combined strong financial execution with a steady cadence of strategic and clinical updates. Earnings on Feb 19, 2026 showed double‑digit revenue growth and improved profitability, yet the stock fell 4.98%. Preliminary 2025 highlights at the J.P. Morgan conference on Jan 12, 2026 also preceded a 5.82% decline despite upbeat guidance. Management strengthened the Board with Jason Patten on Mar 12, 2026, again followed by a negative move. Today’s ACC.26 data and AI/education initiatives fit this pattern of constructive news against a weaker tape.

Market Pulse Summary

This announcement highlights additional large real‑world datasets showing substantial arrhythmia bur...

Analysis

This announcement highlights additional large real‑world datasets showing substantial arrhythmia burden across CKM and obesity populations, reinforcing the diagnostic yield of the Zio ambulatory ECG service. It also underscores iRhythm’s push into AI-enabled care and clinician education through iRhythm Academy. Historically, the company has paired growing clinical evidence with revenue expansion and profitability improvements. Investors may watch future updates on clinical adoption, health‑system partnerships, and AI-driven patient selection, along with how these initiatives support longer-term growth.

Key Terms

ambulatory ecg, arrhythmias, cardiometabolic, atrial fibrillation, +2 more

6 terms

ambulatory ecg medical

"using the Zio® ambulatory ECG portfolio."

An ambulatory ECG is a small, wearable device or set of sensors that records a person’s heart rhythm continuously while they go about their daily life, allowing doctors to catch irregular beats or abnormal patterns that short clinic tests might miss. For investors, it signals demand for monitoring devices, data services and related medical testing — like having a security camera for your heart — because wider use, reimbursement and clear clinical value can drive sales, recurring revenue and partnerships in the healthcare market.

arrhythmias medical

"demonstrate a high prevalence of clinically actionable arrhythmias across CKM"

Arrhythmias are disturbances in the heart’s normal rhythm, where the heartbeat may be too fast, too slow, or irregular—think of the heart like a metronome that is skipping or racing. For investors, they matter because treatments, devices, or tests that diagnose or control arrhythmias can drive drug approvals, device sales, litigation risk, and patient outcomes, all of which affect revenue, regulatory timelines, and market value.

cardiometabolic medical

"arrhythmias are common, early, and often silent across cardiometabolic patient"

Cardiometabolic describes health conditions that affect the heart and the body’s metabolism—most commonly heart disease, high blood pressure, type 2 diabetes and obesity—that often occur together and share common causes. Investors care because these linked conditions drive large, predictable demand for drugs, medical devices and long-term care, and changes in treatment options, guidelines or costs can materially affect healthcare company revenues and government spending much like a problem in an engine and its fuel system impacts the whole vehicle.

atrial fibrillation medical

"Higher body weight was associated with greater likelihood of atrial fibrillation (AF)"

Atrial fibrillation is a common heart rhythm problem in which the heart’s upper chambers quiver instead of delivering steady, strong pumps, like a washing machine on an unbalanced cycle. It matters to investors because it increases use of medications, medical devices, hospital care and long‑term monitoring, drives demand for new treatments and diagnostics, and can affect healthcare costs, regulatory decisions and revenue prospects across drug, device and insurance markets.

bmi medical

"with Zio and where BMI or weight-related diagnostic codes were available."

Body mass index (BMI) is a simple number calculated from a person’s weight and height that classifies them as underweight, normal weight, overweight, or obese; think of it as a quick ratio like miles per gallon for body size. Investors watch BMI because shifts in population averages influence demand for healthcare services, drugs, medical devices, and insurance costs, and they can signal longer-term trends in workforce health and public spending.

artificial intelligence technical

"advances in artificial intelligence and their translation into routine"

Artificial intelligence is the ability of computers and machines to perform tasks that typically require human thinking, such as understanding language, recognizing patterns, or making decisions. For investors, it matters because AI can enhance efficiency, uncover new insights, and enable smarter strategies, potentially impacting the value and performance of companies that develop or utilize this technology.

AI-generated analysis. Not financial advice.

• Data presented at ACC.26 demonstrate a high prevalence of clinically actionable arrhythmias across CKM patient populations using the Zio^® ambulatory ECG portfolio.^1,2
  
• Chief Medical Officer Mintu Turakhia, MD, MS, delivered the 57th Annual Louis F. Bishop Keynote on scaling AI in cardiology and translating advances into clinical practice.
  
• iRhythm Academy launch expands access to clinician education at scale in ambulatory cardiac monitoring as the field continues to advance.
  

SAN FRANCISCO, March 30, 2026 (GLOBE NEWSWIRE) -- iRhythm Holdings, Inc. (NASDAQ: IRTC) announced results from three retrospective analyses presented at the American College of Cardiology (ACC) 2026 Annual Scientific Sessions in New Orleans, March 28–30, 2026, that add to the growing body of clinical evidence supporting the benefits of its Zio^® ambulatory ECG monitoring service across patient populations.^1,2 The data provide insights into the timing and incidence of clinically relevant arrhythmias and highlight opportunities to improve care for patients along the cardiovascular-kidney-metabolic (CKM) continuum.

iRhythm also highlighted its leadership in advancing AI in cardiology, with Chief Medical Officer Mintu Turakhia, MD, MS, Clinical Professor of Medicine at Stanford University, delivering the 57th Annual Louis F. Bishop Keynote, titled “Scaling AI in Cardiology: Moving From Paper and Podium to Product,” and announced the launch of iRhythm Academy, a clinician education platform.

High Prevalence of Clinically Actionable Arrhythmias Across the CKM Continuum, Highlighting Increased Risk for Arrhythmias in this Patient Population

Two abstracts presented at ACC.26 reported the results of retrospective analyses of the incidence of arrhythmias in patients across the CKM disease continuum.^3,4 Each study utilized data from the iRhythm clinical data warehouse linked to commercial fee-for-service and government-sponsored plans claims data. Findings from both studies enhance the understanding of how CKM risk factors influence the incidence of arrhythmias, highlighting that clinically relevant arrhythmias are not limited to patients with more advanced comorbid conditions or disease states.

Arrhythmias in Patients with Diabetes and Chronic Kidney Disease Detected by Long-Term Ambulatory ECG Monitoring³ (Abstract #1474-105) evaluated the prevalence of arrhythmias detected in a cohort of 657,147 individuals in the U.S. who received 14-day continuous ambulatory monitoring linked to commercial fee-for-service or Medicare Advantage claims. The cohort had a mean age of 59 years and was 58% female. Clinically actionable arrhythmias were more commonly identified in patients with chronic kidney disease (CKD), with or without diabetes:

• 11% of patients had diabetes, 4% had chronic kidney disease, and 4% had both conditions—together representing nearly 20% of the overall cohort.
• After accounting for differences in age, clinically actionable arrhythmias affected 48% of patients with CKD and 47% of patients with both diabetes and CKD, compared with 39% of patients with diabetes alone and 35% of patients with neither condition.
• Arrhythmia risk increased across kidney-metabolic phenotypes, highest in CKD (with or without diabetes), with diabetes alone also increasing risk—highlighting the value of targeted rhythm monitoring in patient populations at higher risk for arrhythmia.
  

Incidence of Arrhythmias in Patients with Obesity Detected by Long-Term Ambulatory ECG Monitoring⁴ (Abstract # 1403-107) evaluated the prevalence of arrhythmias of arrhythmias detected 162,531 individuals in the U.S. who received 14-day long-term continuous monitoring (LTCM) with Zio and where BMI or weight-related diagnostic codes were available. The cohort had a mean age of 58 years and was 65% female. Higher body weight was associated with greater likelihood of atrial fibrillation (AF) detection:

• The prevalence of detected AF increased with weight, rising from 4.5% in normal/underweight patients to 6.5% in patients with severe obesity.
• After accounting for differences in age, sex, and comorbidities, patients with severe obesity had nearly threefold higher odds of AF detection compared with normal/underweight patients (adjusted odds ratio of 2.8).
• Nearly two-thirds of patients in this cohort had obesity or severe obesity, highlighting excess weight as a common and potentially modifiable risk factor for AF.
  

Expanding Evidence Highlights the Opportunity for Earlier Detection and Diagnosis

Data presented at ACC.26 build on prior real-world evidence demonstrating that arrhythmias are common, early, and often silent across cardiometabolic patient populations. Findings from two large-scale, real-world studies^5,6 presented at the American Diabetes Association’s 85th Scientific Sessions in June 2025 (ADA 2025) demonstrated that arrhythmias preceded 43% of diabetes and 59% of CKD cases in the study population. Many patients in one study subsequently developed clinically actionable arrhythmia or major cardiovascular events. Three large-scale real-world analyses presented at the American Heart Association Scientific Sessions 2025 (AHA 2025)^7-9 similarly revealed arrhythmia risk emerging earlier across the CKM syndrome continuum. These findings are extended by ACC.26 data demonstrating that the Zio ambulatory ECG service has a high diagnostic yield in these patient populations,^3,4 enabling earlier identification of clinically actionable arrhythmias.

With an estimated 27 million people in the U.S. at risk for undiagnosed arrhythmias each year,¹⁰ iRhythm is committed to reaching patients sooner and has been advancing a data-driven, proactive cardiac monitoring approach deployed with healthcare systems focused on population health management and value-based care goals. Building on this foundation, in 2025, iRhythm announced a collaboration with Lucem Health to apply predictive AI¹¹ to flag patients at elevated risk for arrhythmias, including those with diabetes and CKD, enabling more targeted selection of patients for proactive monitoring and more timely diagnosis and clinical decision-making.

Scaling AI in Cardiology and Expanding Education at Scale

In addition to the data presentations at ACC.26, Mintu Turakhia, MD, MS, Chief Medical and Scientific Officer and EVP, Advanced Technologies at iRhythm, and Clinical Professor of Medicine at Stanford University, delivered the 57th Annual Louis F. Bishop Keynote, titled “Scaling AI in Cardiology: Moving From Paper and Podium to Product.” The keynote addressed the gap between advances in artificial intelligence and their translation into routine cardiovascular care.

Drawing on iRhythm’s platform, its application of advanced AI in cardiac monitoring, and 20-year history, Dr. Turakhia emphasized how AI must function as an infrastructural backbone—integrating multiple streams of data, extending AI to new clinical domains, operationalized within clinical workflows, and accountable for real-world outcomes.

“The primary barrier to impact is no longer technical development or model performance — most AI across diagnostics, clinical decision support, and other domains work well. We need to think of these tools not as point solutions or standalone tests, but rather as critical clinical infrastructure and integrated systems that are safely and responsibly deployed,” said Dr. Turakhia.

iRhythm also launched iRhythm Academy, an education platform offering interactive courses, webinars, publications, and micro-learning modules for healthcare professionals focused on ambulatory cardiac monitoring, extending access to education at scale as the field continues to advance.

iRhythm also announced an upcoming update to the MyZio^® mobile app, which supports patients throughout their ECG monitoring journey with Zio, with the addition of Spanish-language functionality to support patient accessibility.¹²

Data presented at ACC.26 build on iRhythm’s comprehensive clinical evidence program, encompassing more than 135 original research manuscripts, insights derived from over 3 billion hours of curated heartbeat data, and nearly 12 million patient reports since the company’s inception¹³—underscoring its ongoing commitment to expanding evidence that supports improved patient outcomes.

About iRhythm Holdings
iRhythm is a leading digital health care company that creates trusted solutions that detect, predict, and prevent disease. Combining wearable biosensors and cloud-based data analytics with powerful proprietary algorithms, iRhythm distills data from millions of heartbeats into clinically actionable information. Through a relentless focus on patient care, iRhythm’s vision is to deliver better data, better insights, and better health for all.

Forward-Looking Statements
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and the Private Securities Litigation Reform Act of 1995. These statements can be identified by words such as “anticipate,” “estimate,” “expect,” “intend,” “will,” “may,” “project,” “plan,” “believe,” “target,” and similar expressions that relate to future events or outcomes.

Forward-looking statements in this press release include, but are not limited to, statements regarding the significance and potential impact of the data presented; the clinical utility and performance of iRhythm’s Zio® ambulatory ECG monitoring service; the potential to enable earlier detection and diagnosis of arrhythmias; the application of artificial intelligence and predictive analytics to identify patients at elevated risk for arrhythmias; and the ability to expand access to clinician education and improve patient care through initiatives such as iRhythm Academy.

These statements are based on current assumptions and expectations and are subject to risks and uncertainties that could cause actual results to differ materially. These risks and uncertainties include, among others, the timing, interpretation, and acceptance of clinical data; the ability to translate findings into clinical practice; regulatory and reimbursement developments; market adoption of iRhythm’s products and services; and the risks described in the section entitled “Risk Factors” in iRhythm’s most recent filings with the Securities and Exchange Commission, including its Forms 10-K and 10-Q.

These forward-looking statements speak only as of the date of this press release, and iRhythm undertakes no obligation to update them, except as required by law.

Media Contact:
Kassandra Perry
mediarelations@irhythmtech.com

Investor Contact:
Stephanie Zhadkevich
investors@irhythmtech.com

1. The Zio AT device is not intended for use in critical care patients because the reporting timeliness is not consistent with life-threatening arrhythmias such as ventricular fibrillation. Refer to Zio AT Clinical Reference Manual for additional information.
2. Do not use Zio AT for patients with symptomatic episodes where variations in cardiac performance could result in immediate danger to the patient or when real-time or in-patient monitoring should be prescribed.
3. Ashburner JM et al. “Arrhythmias in Patients with Diabetes and Chronic Kidney Disease Detected by Long-Term Ambulatory ECG Monitoring.” American College of Cardiology 2026 Annual Scientific Session & Expo, 2026. New Orleans, Louisiana.
4. Battisti AJ. “Incidence of Arrhythmias in Patients with Obesity Detected by Long-Term Ambulatory ECG Monitoring.” American College of Cardiology 2026 Annual Scientific Session & Expo, 2026. New Orleans, Louisiana.
5. “Incidence of Cardiac Arrhythmias in Patients with Diabetes: a Real-World Study.” American Diabetes Scientific Sessions, 2025; Chicago, Illinois.
6. Russo P et al. “Incidence and Timing of Major Arrhythmias in T2D and CKD:A Real-World Analysis.” American Diabetes Scientific Sessions, 2025; Chicago, Illinois.
7. Russo P et al. “Onset of Arrhythmias in the CKM Continuum: Real-World Insights From a National Cohort.” American Heart Association Scientific Sessions, 2025; New Orleans, Louisiana.
8. Russo P et al. “CKD and CKM Syndrome: Accelerated Progression to Arrhythmias in a National Cohort.” American Heart Association Scientific Sessions, 2025; New Orleans, Louisiana.
9. Russo P et al. “Arrhythmias as Early Predictors of Chronic Kidney Disease: Real-World Evidence From a National Cardio-Kidney-Metabolic Cohort.” American Heart Association Scientific Sessions, 2025; New Orleans, Louisiana.https://www.jacc.org/doi/10.1016/S0735-1097%2823%2902786 9 https://www.ajmc.com/view/assessment-of-variation-in-ambulatory-cardiac-monitoring-among-commercially-insured-patients
10. iRhythm internal estimate based on analysis of public and proprietary sources, including U.S. Census Bureau data, CDC healthcare utilization data, Medicare Public Use Files, IQVIA, Komodo Health, Definitive Healthcare, and peer-reviewed literature on arrhythmia prevalence, symptom presentation, and diagnostic pathways. Full source list available upon request.
11. Predictive Arrhythmia Solutions does not represent functionality of any Zio branded medical device.
12. The MyZio^® mobile app for patients is not a medical device and is not intended to diagnose, treat, cure, or prevent any disease.
13. Data on file. iRhythm Technologies, 2025.
    

FAQ

What did iRhythm (IRTC) present at ACC.26 on March 30, 2026?

They presented retrospective analyses showing high arrhythmia prevalence across CKM populations and obesity-related AF increases. According to the company, findings include 48% arrhythmia prevalence in CKD and AF rising to 6.5% in severe obesity.

How does the ACC.26 data affect iRhythm's clinical evidence for Zio (IRTC)?

The data strengthen Zio's real-world diagnostic yield in cardiometabolic populations and CKD. According to the company, analyses support earlier detection opportunities and higher arrhythmia rates in CKD and obesity cohorts.

What specific arrhythmia rates did iRhythm report for patients with CKD and diabetes (IRTC)?

After age adjustment, 48% of patients with CKD and 47% with both diabetes+CKD had clinically actionable arrhythmias. According to the company, these rates exceeded those for diabetes alone (39%) and neither condition (35%).

What was the relationship between obesity and AF detection in the ACC.26 findings for IRTC?

AF detection rose from 4.5% in normal/underweight to 6.5% in severe obesity, with adjusted odds ratio 2.8. According to the company, higher body weight substantially increased AF detection likelihood.

What new education and patient-access initiatives did iRhythm announce at ACC.26 (IRTC)?

They launched iRhythm Academy for clinician education and announced a Spanish-language update to the MyZio patient app. According to the company, these expand clinician training and patient accessibility for ambulatory ECG monitoring.